Cesar Briceno, MD
Ophthalmology · Philadelphia, PANPI 1427235035
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amgen at 34.9% of the total. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $1203.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$32K
- Genentech USA, Inc.$19K
- F. Hoffmann-la Roche AG$15K
- Genentech, Inc.$11K
- Argenx US, Inc.$7K
- Regeneron$6K
- plus $117 from 4 others
Across 9 payments — averaging $44,081 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$395K
- Amgen$1K
What the payments were for
- Consulting fees$53,46258%
- Speaking & faculty fees$20,00022%
- Travel & lodging$15,77917%
- Food & beverage$2,2012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 34 | $31,937 |
| Genentech USA, Inc. | 12 | $19,179 |
| F. Hoffmann-la Roche AG | 5 | $15,416 |
| Genentech, Inc. | 12 | $11,255 |
| Argenx US, Inc. | 1 | $7,200 |
| Regeneron | 7 | $6,338 |
| Tarsus Pharmaceuticals, Inc. | 2 | $48 |
| Stryker | 1 | $31 |
| Kerecis Limited | 1 | $27 |
| Polynovo North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,442 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 138 | $2,298 |
| Azelastine Hcl | 45 | $920 |
| Cromolyn Sodium | 19 | $644 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 50 | $614 |
| Cephalexin | 13 | $43 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.